Administration of convalescent plasma obtained from survivors of COVID-19 within 72 hours of onset of mild symptoms in elderly patients with COVID-19 was associated with a significant reduction in the risk of development of severe respiratory disease.
This was a randomized, open-label, multicenter trial of intravenous convalescent plasma infusion (4 mL/kg to 13 mL/kg) therapy. Convalescent plasma therapy was not associated with improvements in mortality or time to clinical improvement.
The number and variety of anticoagulants have expanded greatly during the past decade. Because of the large number of individuals on anticoagulation for various conditions, anticoagulated patients assuredly will present as trauma patients.